17 June 2022 - The aim of this study was to find ways of bridging the gap in opinions concerning health technology assessment in reimbursement submission between manufacturers and payers to avoid access delays for patients of vital medicines such as oncology drugs. 

This was done by investigating differences and similarities of opinion among key stakeholders in Australia.

Read International Journal of Technology Assessment in Health Care article